Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360199 | 1.00 | GBA1 (0.42) | GBA1GAATHRBGBA2CHRM2 | |
| SCHEMBL15186923 | 1.00 | GBA1 (0.42) | GBA1GAATHRBGBA2CHRM2 | |
| SCHEMBL13942058 | 1.00 | GBA1 (0.42) | GBA1GAATHRBGBA2CHRM2 | |
| SCHEMBL3317512 | 0.82 | GAA (0.41) | GBA1GAATHRBGBA2 | |
| SCHEMBL21292661 | 0.82 | GAA (0.41) | GBA1GAATHRBGBA2 | |
| SCHEMBL16279687 | 0.82 | GAA (0.41) | GBA1GAATHRBGBA2 | |
| SCHEMBL30064858 | 0.82 | GAA (0.41) | GBA1GAATHRBGBA2 | |
| SCHEMBL13032050 | 0.81 | GBA1 (0.42) | GBA1GAATHRBGBA2 | |
| SCHEMBL27156378 | 0.80 | HCRTR2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27156656 | 0.80 | HCRTR2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071324-B2 | Systems and methods for sequencing by hybridization | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2006-07-04 | — | — | US | claimed |
| US-20030064382-A1 | Systems and methods for sequencing by hybridization | NABSYS 2.0 LLC | 2003-04-03 | — | — | US | claimed |
| US-8247540-B2 | Caged nucleotides and oligonucleotides and their application | DEITERS ALEXANDER (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100099159-A1 | CAGED NUCLEOTIDES AND OLIGONUCLEOTIDES AND THEIR APPLICATION | DEITERS ALEXANDER | 2010-04-22 | — | — | US | disclosed |
| US-7071324-B2 | Systems and methods for sequencing by hybridization | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20030064382-A1 | Systems and methods for sequencing by hybridization | NABSYS 2.0 LLC | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099159-A1 | CAGED NUCLEOTIDES AND OLIGONUCLEOTIDES AND THEIR APPLICATION | RNGTT, NT5C3B, ADAR | GBA1 332/4885GAA 552/4885THRB 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.